"Correlation between circulating tumour DNA and metabolic tumour burden" by Ashleigh McEvoy, Lydia Warburton et al.
 

Document Type

Journal Article

Publication Title

BMC Cancer

Publisher

BioMed Central Ltd

School

School of Medical and Health Sciences

RAS ID

27192

Comments

McEvoy, A. C., Warburton, L., Al-Ogaili, Z., Celliers, L., Calapre, L., Pereira, M. R., ... & Gray, E. S. (2018). Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC cancer, 18(1), 726. Available here.

Abstract

Background: Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is a need to understand the correlation between ctDNA levels and the patients' overall metabolic tumour burden (MTB). Methods: Thirty-two treatment naïve metastatic melanoma patients were included in the study. MTB and metabolic tumour volume (MTV) was measured by 18F-fluoro-D-glucose positron emission tomography/computed tomography (FDG PET/CT). Plasma ctDNA was quantified using droplet digital PCR (ddPCR). Results: CtDNA was detected in 23 of 32 patients. Overall, a significant correlation was observed between ctDNA levels and MTB (p

DOI

10.1186/s12885-018-4637-6

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Plum Print visual indicator of research metrics
PlumX Metrics
  • Citations
    • Citation Indexes: 83
    • Patent Family Citations: 1
    • Policy Citations: 1
  • Usage
    • Downloads: 100
    • Abstract Views: 22
  • Captures
    • Readers: 85
see details

Share

 
COinS
 
 
 
BESbswy